Comparative accounts of probiotic properties of spore and vegetative cells of Bacillus clausii UBBC07 and in silico analysis of probiotic function

Genetic and phenotypic assessments for the safety of probiotic Bacillus clausii 088AE

In this study, we report on whole genome sequence analysis of clinically documented, commercial probiotic Bacillus clausii 088AE and genome features contributing to probiotic properties. The whole genome sequence of B. clausii 088AE generated a single scaffold of 4,598,457 bp with 44.74 mol% G + C. This assembled genome sequence annotated by the RAST resulted in 4371 coding genes, 75 tRNAs, and 22 rRNAs. Gene ontology classification indicated 39.5% proteins with molecular function, 44.24% cellular component, and 16.25% proteins involved in biological processes. In taxonomic analysis, B. clausii 088AE shared 99% identity with B. clausii DSM 8716. The gene sequences related to safety and genome stability such as antibiotic resistance (840), virulence factors (706), biogenic amines (1), enterotoxin (0), emetic toxin (0), lanthipeptides (4), prophage (4) and clustered regularly interspaced short palindromic repeats (CRISPR) sequences (11), were identified and evaluated for safety and functions. The absence of functional prophage sequences and the presence of CRISPR indicated an advantage in genome stability. Moreover, the presence of genome features contributing to probiotic characteristics such as acid, and bile salt tolerance, adhesion to the gut mucosa, and environmental resistance ensure the strains survivability when consumed as a probiotic. In conclusion, the absence of risks associated with sequences/genes in the B. clausii 088AE genome and the presence of essential probiotic traits confirm the strain to be safe for use as a probiotic.

Bacillus clausii UBBC-07 in the symptom management of upper respiratory tract infections in children: a double blind, placebo-controlled randomised study

In children, upper respiratory tract infections (URTIs) are one of the most common causes of infections which often require outpatient consultations with the doctor. The purpose of this study was to evaluate the effect of probiotic Bacillus clausii UBBC-07 on symptom management of URTIs in children. In this double blind, randomised, placebo-controlled study, 90 children (age 4-7 years) with URTIs were equally divided into two groups, the probiotic and placebo. The children were instructed to take B. clausii UBBC-07 spores (2×109 per 5 ml vial) or placebo suspension daily twice for three months. The total duration of the study was 6 months, 3 months treatment and 3 months follow-up period. The parameters assessed were the mean number of URTIs, duration and severity of URTIs, absenteeism from school/childcare and immunity parameters, such as immunoglobulin (Ig)M, IgG, IgE and salivary IgA levels. At the end of treatment, there was a significant decrease in the number, duration and severity of URTIs in the probiotic treated group as compared to the baseline and placebo. IgE levels were significantly decreased and salivary IgA levels were significantly increased in the probiotic treated group suggesting probiotic mediated Th1/Th2 immune homeostasis to alleviate URTIs in children. In conclusion, B. clausii UBBC-07 may help in the reduction of symptoms of URTIs. The trial was registered prospectively with the Clinical Trial Registry of India (CTRI Reg. No: CTRI/2018/08/015282).

Different effects of Bacillus coagulans vegetative cells and spore isolates on constipation-induced gut microbiota dysbiosis in mice

Bacillus coagulans (B. coagulans) can improve and prevent functional gastrointestinal disorders. However, there has been little discussion in the literature on the difference between spores and vegetative cells for relieving constipation. The purpose of this study was to determine the efficacy of Bacillus coagulans (B. coagulans) vegetative cells and spores against loperamide-induced constipation in mice. According to our findings, B. coagulans vegetative cells and spores differ in their ability to relieve loperamide-induced constipation. Two of the three strains of B. coagulans spores used in this experiment, B. coagulans GBI-30 6086 and B. coagulans 90, were significantly different from the model group in relieving constipation. This mainly manifested as a decreased time required for first black stool defecation (by 52 and 79 min, respectively), and increased counts of the first black stools in 5 h (by 15 and 8, respectively), the small intestine transit rate (by 23.31% and 20.52%, respectively), and the concentration of SCFAs. While the administration of vegetative cells could only relieve some indicators of intestinal transit disorders and dysbacteriosis caused by constipation. Spores of B. coagulans GBI-30 6086 and B. coagulans 90 had higher survival rates in the simulated gastrointestinal tract environment, which indicated that the functional modes of the three strains were different and had a strong relationship with the morphology of the bacteria. B. coagulans GBI-30 6086 and B. coagulans 90 spores alleviate constipation by increasing the abundances of Actinobacteria, Deferribacteres, and Lachnospiraceae UCG-006 (which were positively correlated with SCFAs) and decreasing the abundances of Cyanobateria and Rikenellaceae_RC9_gut group (which were negatively correlated with SCFAs) and the levels of Ruminococcaceae UGC-014 and Alistipes. In this study, the effects of probiotics in the form of spore or vegetative cell were compared, and the optimal preparation form was determined, providing a theoretical basis for the application of probiotics of B. coagulans to relieve constipation.